Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, has been added to the Russell 2000 and Russell 3000 Indexes. The inclusion became effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution. This development marks a significant milestone for the company, enhancing its visibility among investors.

The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market, while the Russell 3000 Index tracks the largest 3,000 U.S. stocks by market capitalization. Elicio's addition to both indexes reflects its growing market presence and may lead to increased trading activity as index funds and portfolios tracking these benchmarks adjust their holdings.

The annual reconstitution of Russell indexes ensures that the indexes accurately represent the current U.S. equity market landscape. Elicio's inclusion underscores its progress in developing immunotherapies for KRAS-driven cancers, a key focus area for the company.

The Schall Law Firm is investigating claims on behalf of investors of Elicio Therapeutics, Inc. regarding potential violations of securities laws. The investigation follows a significant decline in the company's stock price after Elicio announced that its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint. On June 15, 2026, Elicio’s stock price fell by almost 71%, closing at $4.08 per share after dropping $9.97.

The investigation centers on whether Elicio issued false and/or misleading statements and/or failed to disclose information pertinent to investors. This scrutiny arises after the company reported that the AMPLIFY-7P study did not achieve the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population. Pomerantz LLP is also investigating similar claims regarding potential securities fraud and other unlawful business practices.

Clinical Context

Elicio had previously reported 100% confirmed complete radiographic and complete metabolic responses in three metastatic pancreatic cancer patients who progressed on ELI-002 7P treatment and subsequently received Bristol-Myers Squibb & Co.’s Opdivo (nivolumab)-based therapy. These patients demonstrated persistent mutant KRAS (mKRAS)-specific T cell responses and were microsatellite stable (MSS) / mismatch repair proficient (MMR-p), a population historically less responsive to immune checkpoint inhibitors.

Future Development Plans

Despite the Phase 2 failure, Elicio outlined a refined Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic cancer. Subject to funding, the company plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with standard gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naïve metastatic mKRAS pancreatic cancer. The company intends to use findings from the AMPLIFY-7P study to evaluate checkpoint inhibitor combinations and inform future development strategies.